Unobio Information

Most drug programs don't fail at discovery. They fail at translation — because the biology tested against was never the biology that matters. Unobio closes that gap. We identify, license, and develop drug assets using AI-driven landscape mapping paired with patient-derived translational biology. Every candidate we advance is pressure-tested against human biology before IND — not after. Demonstrated 94% concordance between in-silico predictions and observed translational outcomes. We partner with pharma and biotech on asset licensing and co-development. We find the drugs worth advancing. → unobio.com/licensing-pipeline